生物技术公司Techne Corporation（TECH）今日盘前股价大跌9.17%，引发市场广泛关注。此次股价下跌主要源于公司第一季度财报未能达到市场预期。
根据公司最新发布的财报，Techne Corporation第一季度收入为2.866亿美元，低于分析师预期的2.912亿美元。公司最大的蛋白质科学部门销售额下降1%至2.022亿美元，而诊断和基因组学部门的季度收入更是下降4%至7950万美元。这些数据显示公司各主要业务板块均面临增长压力。
公司首席执行官金·凯尔德曼（Kim Kelderman）表示，虽然美国学术终端市场出现了令人鼓舞的稳定迹象，大型制药客户的表现也持续强劲，但新兴生物技术公司的融资困境依然存在。特别是中国生物技术融资环境疲软，导致对公司产品的需求低迷。此外，与特朗普关税和学术资助政策有关的不确定性预计将延续到2026财年，这些因素都对公司业绩造成了压力。面对这些挑战，投资者对Techne Corporation的短期增长前景产生了担忧，导致股价出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.